JP7556882B2 - 速崩壊カンナビノイド錠剤 - Google Patents

速崩壊カンナビノイド錠剤 Download PDF

Info

Publication number
JP7556882B2
JP7556882B2 JP2021561780A JP2021561780A JP7556882B2 JP 7556882 B2 JP7556882 B2 JP 7556882B2 JP 2021561780 A JP2021561780 A JP 2021561780A JP 2021561780 A JP2021561780 A JP 2021561780A JP 7556882 B2 JP7556882 B2 JP 7556882B2
Authority
JP
Japan
Prior art keywords
tablet
cannabinoids
cannabinoid
composition
module
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021561780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529037A5 (cg-RX-API-DMAC10.html
JP2022529037A (ja
Inventor
ハイジ・ツィーグラー・ブルーン
ドゥールト・シャキンガー・ボーセン
ブルーノ・プロヴストガールド・ニールセン
Original Assignee
ノルディックカン・アー/エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA3040513A external-priority patent/CA3040513C/en
Priority claimed from CA3040547A external-priority patent/CA3040547C/en
Priority claimed from CA3040532A external-priority patent/CA3040532C/en
Priority claimed from US16/386,477 external-priority patent/US10925853B2/en
Priority claimed from US16/713,580 external-priority patent/US11633351B2/en
Priority claimed from CA3065042A external-priority patent/CA3065042C/en
Application filed by ノルディックカン・アー/エス filed Critical ノルディックカン・アー/エス
Publication of JP2022529037A publication Critical patent/JP2022529037A/ja
Publication of JP2022529037A5 publication Critical patent/JP2022529037A5/ja
Publication of JP7556882B2 publication Critical patent/JP7556882B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2021561780A 2019-04-17 2020-04-17 速崩壊カンナビノイド錠剤 Active JP7556882B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
CA3040532 2019-04-17
CA3040513A CA3040513C (en) 2019-04-17 2019-04-17 An oral cannabinoid tablet
US16/386,477 US10925853B2 (en) 2019-04-17 2019-04-17 Oral cannabinoid tablet
CA3040532A CA3040532C (en) 2019-04-17 2019-04-17 Lozenge for improved delivery of cannabinoids
CA3040547 2019-04-17
US16/386,477 2019-04-17
CA3040547A CA3040547C (en) 2019-04-17 2019-04-17 Cannabinoid lozenge formulation
CA3040513 2019-04-17
CA3065042 2019-12-13
US16/713,580 US11633351B2 (en) 2019-12-13 2019-12-13 Fast disintegrating cannabinoid tablets
CA3065042A CA3065042C (en) 2019-12-13 2019-12-13 Fast disintegrating cannabinoid tablets
US16/713,580 2019-12-13
PCT/DK2020/050102 WO2020211915A1 (en) 2019-04-17 2020-04-17 Fast disintegrating cannabinoid tablets

Publications (3)

Publication Number Publication Date
JP2022529037A JP2022529037A (ja) 2022-06-16
JP2022529037A5 JP2022529037A5 (cg-RX-API-DMAC10.html) 2023-04-24
JP7556882B2 true JP7556882B2 (ja) 2024-09-26

Family

ID=70802555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021561780A Active JP7556882B2 (ja) 2019-04-17 2020-04-17 速崩壊カンナビノイド錠剤

Country Status (12)

Country Link
EP (2) EP4268815A3 (cg-RX-API-DMAC10.html)
JP (1) JP7556882B2 (cg-RX-API-DMAC10.html)
CN (1) CN113784704A (cg-RX-API-DMAC10.html)
AU (1) AU2020258631B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021020523A2 (cg-RX-API-DMAC10.html)
DK (1) DK3920891T3 (cg-RX-API-DMAC10.html)
ES (1) ES2975266T3 (cg-RX-API-DMAC10.html)
FI (1) FI3920891T3 (cg-RX-API-DMAC10.html)
MX (1) MX2021012712A (cg-RX-API-DMAC10.html)
PL (1) PL3920891T3 (cg-RX-API-DMAC10.html)
WO (1) WO2020211915A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202107389B (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020412501A1 (en) * 2019-12-24 2022-08-18 Cannadol Pharmaceuticals Ltd Compositions comprising terpenes and their use in the treatment or alleviation of pain or anxiety
TWI923583B (zh) * 2020-04-14 2026-05-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽之用於經口投予之醫藥組成物
LT4243797T (lt) * 2020-11-16 2026-06-10 Orcosa Inc. Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui
US11672761B2 (en) * 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114748429A (zh) * 2020-12-29 2022-07-15 汉义生物科技(北京)有限公司 一种水溶性大麻素制剂及其制备方法
JP2023010677A (ja) * 2021-07-09 2023-01-20 株式会社東洋新薬 固形組成物
JP2023010676A (ja) * 2021-07-09 2023-01-20 株式会社東洋新薬 固形組成物
US20240415853A1 (en) * 2023-03-21 2024-12-19 Fertin Pharma A/S Cannabinoid Self-Emulsifying Systems
JP2025529608A (ja) * 2023-07-24 2025-09-09 ポビバ コーポレーション てんかんを処置する為の組成物及び方法
DK202330231A1 (en) * 2023-09-27 2025-04-10 Fertin Pharma As Cannabidiol for alleviating xerostomia
CN118021744A (zh) * 2024-02-05 2024-05-14 谛邈生物科技(北京)有限公司 一种大麻二酚型大麻素化合物冻干闪释片及其制备方法
DK202430722A1 (en) * 2024-11-25 2026-06-09 Fertin Pharma As Sugar free soft chew tablets

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512943A (ja) 2001-02-14 2005-05-12 ジーダブリュー ファーマ リミテッド 医薬製剤
JP2007504207A (ja) 2003-09-05 2007-03-01 アロー・ナンバー7・リミテッド 口腔内ドラッグ・デリバリー
JP2010532367A (ja) 2007-06-29 2010-10-07 マクニール−ピーピーシー・インコーポレーテツド 2部分からなるロゼンジ剤形
US20110097283A1 (en) 2008-03-26 2011-04-28 Mareda Holding Bv Chewing gum compositions comprising cannabinoids
WO2015131269A1 (en) 2014-03-04 2015-09-11 Pharmascience Inc. Orally disintegrating tablet of nabilone comprising mannitol-based granules
US20160015683A1 (en) 2014-07-21 2016-01-21 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
US20160220593A1 (en) 2015-02-02 2016-08-04 Axim Biotechnologies, Inc. Cannabinoid and sugar alcohol complex, methods to make and use
US20170368020A1 (en) 2016-06-22 2017-12-28 Mastix, Llc Oral compositions delivering therapeutically effective amounts of cannabinoids
WO2018023166A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US20180221332A1 (en) 2017-02-05 2018-08-09 CannTab Therapeutics Limited Flash-Melt Cannabinoid Formulations
US20180263913A1 (en) 2017-03-16 2018-09-20 CannTab Therapeutics, Limited Modified Release Multi-Layer Tablet Cannabinoid Formulations
US20180289665A1 (en) 2014-12-07 2018-10-11 One World Cannabis Ltd Use of cannabis to treat migraine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2664315C (en) * 2006-09-15 2016-01-19 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
EP2164462B1 (de) * 2007-06-06 2017-05-31 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
WO2009151072A1 (ja) * 2008-06-13 2009-12-17 大日本住友製薬株式会社 口腔内速崩壊錠及びその製造方法
KR20130076015A (ko) * 2011-12-28 2013-07-08 주식회사 삼양바이오팜 높은 경도를 갖는 속붕정 및 이의 제조 방법
EP2609912A1 (en) * 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Pharmaceutical combination of fingolimod and nabiximols
JP2020520966A (ja) * 2017-05-22 2020-07-16 ジービーエス グローバル バイオファーマ,インコーポレイテッド Trpv1を標的にするミルセン及びカンナビノイド含有組成物
JP2021513566A (ja) * 2018-02-09 2021-05-27 ニュートリスキ インターナショナル インク.Neutrisci International Inc. スチルベノイドとカンナビノイドとの共結晶を含む組成物

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512943A (ja) 2001-02-14 2005-05-12 ジーダブリュー ファーマ リミテッド 医薬製剤
JP2007504207A (ja) 2003-09-05 2007-03-01 アロー・ナンバー7・リミテッド 口腔内ドラッグ・デリバリー
JP2010532367A (ja) 2007-06-29 2010-10-07 マクニール−ピーピーシー・インコーポレーテツド 2部分からなるロゼンジ剤形
US20110097283A1 (en) 2008-03-26 2011-04-28 Mareda Holding Bv Chewing gum compositions comprising cannabinoids
WO2015131269A1 (en) 2014-03-04 2015-09-11 Pharmascience Inc. Orally disintegrating tablet of nabilone comprising mannitol-based granules
US20160015683A1 (en) 2014-07-21 2016-01-21 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
US20180289665A1 (en) 2014-12-07 2018-10-11 One World Cannabis Ltd Use of cannabis to treat migraine
US20160220593A1 (en) 2015-02-02 2016-08-04 Axim Biotechnologies, Inc. Cannabinoid and sugar alcohol complex, methods to make and use
US20170368020A1 (en) 2016-06-22 2017-12-28 Mastix, Llc Oral compositions delivering therapeutically effective amounts of cannabinoids
WO2018023166A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US20180221332A1 (en) 2017-02-05 2018-08-09 CannTab Therapeutics Limited Flash-Melt Cannabinoid Formulations
US20180263913A1 (en) 2017-03-16 2018-09-20 CannTab Therapeutics, Limited Modified Release Multi-Layer Tablet Cannabinoid Formulations

Also Published As

Publication number Publication date
MX2021012712A (es) 2021-11-12
BR112021020523A2 (pt) 2021-12-07
EP4268815A3 (en) 2024-02-21
EP3920891B1 (en) 2024-02-21
ZA202107389B (en) 2025-04-30
CN113784704A (zh) 2021-12-10
PL3920891T3 (pl) 2024-05-20
ES2975266T3 (es) 2024-07-04
EP4268815A2 (en) 2023-11-01
AU2020258631B2 (en) 2023-11-02
FI3920891T3 (fi) 2024-03-19
AU2020258631A1 (en) 2021-10-28
DK3920891T3 (da) 2024-03-18
JP2022529037A (ja) 2022-06-16
WO2020211915A1 (en) 2020-10-22
EP3920891A1 (en) 2021-12-15

Similar Documents

Publication Publication Date Title
AU2020258631B2 (en) Fast disintegrating cannabinoid tablets
US11903919B2 (en) Oral cannabinoid tablet
CA3040513C (en) An oral cannabinoid tablet
CA3040532C (en) Lozenge for improved delivery of cannabinoids
EP3920890B1 (en) An oral cannabinoid tablet
AU2020260255B2 (en) Cannabinoid lozenge formulation
US20230218512A1 (en) Fast Disintegrating Cannabinoid Tablets
US20260108543A1 (en) Self-Emulsifying Systems For Cannabinoids
US20250261675A1 (en) Cannabinoid Lipid Premixture
CA3065042C (en) Fast disintegrating cannabinoid tablets
KR20260034661A (ko) 칸나비노이드의 지속 방출을 위한 점착성 구강 디스크

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240610

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240819

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240912

R150 Certificate of patent or registration of utility model

Ref document number: 7556882

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150